Repare Therapeutics
Repare is developing new, precision oncology drugs for patients that target specific vulnerabilities of tumor cells.
Launch date
Employees
Market cap
€136m
Enterprise valuation
(€51m) (Public information from Sep 2024)
Share price
$3.5 RPTX
Montreal Quebec (HQ)
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | <1m | 7.6m | 132m | 51.1m | 59.2m | 12.4m | 40.2m |
| % growth | - | 5530 % | 1635 % | (61 %) | 16 % | (79 %) | 223 % |
| EBITDA | (53.6m) | (109m) | (20.1m) | (114m) | (112m) | (175m) | (117m) |
| % EBITDA margin | (39732 %) | (1428 %) | (15 %) | (223 %) | (189 %) | (1408 %) | (291 %) |
| Profit | (53.4m) | (107m) | (29.0m) | (93.8m) | (96.9m) | (161m) | (152m) |
| % profit margin | (39568 %) | (1407 %) | (22 %) | (183 %) | (164 %) | (1300 %) | (379 %) |
| EV / revenue | 6868.9x | 70.8x | 2.1x | 1.6x | -2.0x | -3.3x | -3.7x |
| EV / EBITDA | -17.3x | -5.0x | -13.6x | -0.7x | 1.1x | 0.2x | 1.3x |
| R&D budget | 40.1m | 90.0m | 119m | 134m | - | - | - |
| R&D % of revenue | 29697 % | 1185 % | 90 % | 261 % | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
* | $68.0m | Series A | |
* | $82.5m | Series B | |
* | N/A | $253m | IPO |
* | N/A | $101m | Post IPO Equity |
* | $1.5m | Post IPO Equity | |
| Total Funding | €137m | ||
Related Content
Recent News about Repare Therapeutics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.